AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaatz, G. W.
Right arrow Articles by Rybak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaatz, G. W.
Right arrow Articles by Rybak, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 254-256, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis

Glenn W. Kaatz,1,2,3,* Susan M. Seo,1,2 Jeffrey R. Aeschlimann,3,4 Heather H. Houlihan,3,4 Reneé-Claude Mercier,3,4 and Michael J. Rybak1,3,4

Department of Internal Medicine, Division of Infectious Diseases, School of Medicine,1 Department of Veteran's Affairs Medical Center,2 and College of Pharmacy and Allied Health Professions,3 Wayne State University, and The Anti-Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center,4 Detroit, Michigan 48201

Received 29 August 1997/Returned for modification 21 October 1997/Accepted 10 November 1997

Trovafloxacin is a new fluoronaphthyridone chemically and functionally related to members of the fluoroquinolone class of antimicrobial agents. The in vivo efficacy of the drug was compared with that of vancomycin by using the rabbit model of left-sided endocarditis. Rabbits infected with either a nafcillin-susceptible or -resistant test strain were treated with trovafloxacin (13.3 mg/kg of body weight every 12 h) or vancomycin (25 mg/kg of body weight every 8 h) for 4 days. In comparison with untreated controls, both antimicrobial agents effectively cleared bacteremia and significantly reduced bacterial counts in vegetations and tissues of animals infected with either test strain. No resistance to trovafloxacin emerged in test strains during therapy. We conclude that in this model trovafloxacin is as efficacious as vancomycin is and may serve as a viable alternative to vancomycin for use in humans with similar infections.

* Corresponding author. Mailing address: Department of Internal Medicine, Division of Infectious Diseases, Wayne State University School of Medicine, C3690 Detroit VA Medical Center, 4646 John R, Detroit, MI 48201. Phone: (313) 576-4487. Fax: (313) 576-1112. E-mail: gkaatz{at}juno.com.

Antimicrobial Agents and Chemotherapy, February 1998, p. 254-256, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.